News | ECG | February 02, 2021

Cardiac Insight Speaks Out Against Medicare Decision to Slash Reimbursement Rates and Limit Access to New ECG Technologies 

There has been an increasing trend in cardiology to use longer term remote monitoring wearable ECG tracking devices. This is an example of of the Cardiac Insight Cardea Solo adhesive patch device.

There has been an increasing trend in cardiology to use longer term remote monitoring wearable ECG tracking devices. This is an example of of the Cardiac Insight Cardea Solo adhesive patch device.


February 2, 2021 — Cardiac Insight, Inc. a healthcare company specializing in wearable cardiac sensors and automated electrocardiogram (ECG) analysis, said a recent Medicare reimbursement rate reduction for long-term electrocardiogram (ECG) monitoring is a big set back for patient care.

The rates published by Medicare Administrative Contractor (MAC) Novitas Solutions for CPT codes 93241, 93243, 93245, and 93247 showed up to a 74% reduction in physician reimbursements, Cardiac Insight said. 

“By setting low physician procedure reimbursement on a relatively low-cost, high yield cardiac diagnostic test, CMS and Novitas are ignoring scientific evidence and the professional judgement of thousands of physicians and heart specialists who prescribe ECG wearables because they provide the best and most convenient care for their patients,” explained said Brad Harlow, CEO of Cardiac Insight.

These include the global and technical components for the newly established Category I codes for long-term ECG monitoring, effective Jan. 1, 2021. Novitas provides administrative and claims processing services for state and federal health care programs such as Medicare and Medicaid and is owned by GuideWell.

“By setting low physician procedure reimbursement on a relatively low-cost, high yield cardiac diagnostic test, CMS and Novitas are ignoring scientific evidence and the professional judgement of thousands of physicians and heart specialists who prescribe ECG wearables because they provide the best and most convenient care for their patients,” said Robert G. Hauser, M.D., FACC, FHRS, former president of the Heart Rhythm Society and Emeritus Senior Consulting Cardiologist, Minneapolis Heart Institute. “The Heart Rhythm Society, American College of Cardiology, American Heart Association, and all patient advocacy groups should object to this ruling by Novitas and the approach taken by the Centers for Medicare and Medicaid Services. Their actions are not in the best interest of patients and certainly do not put patient health first.”

“We are astonished and disappointed by the direction CMS and Novitas have taken, specifically Novitas, with its announcement of a 74% average reduction in physician procedure global reimbursement compared to prior Category III tracking CPT code rates. This untenable decision significantly sets back patient care as it will limit access to extended ECG testing for patients and physicians nationwide,” Harlow said. “We have seen firsthand the positive impact prescription, medical grade ECG wearables make to improve the detection, diagnosis and treatment of life-threatening cardiac arrhythmias in patients at risk, especially for those suffering from atrial fibrillation. These extremely low reimbursement rates will have negative repercussions for health outcomes, especially for the increased risk of stroke and heart failure. Providers and patients, particularly seniors, should be outraged by this decision. We plan to seek additional information from GuideWell and Novitas.”

Cardiac Insight provides an all-inclusive seven-day ambulatory ECG system, the Cardea Solo, that includes in-office rapid automated ECG analysis and reporting to detect arrhythmias, including atrial fibrillation. Cardea Solo speeds the time to diagnosis and simplifies the diagnostic process by enabling clinicians to generate an automated report immediately in-house without the need to outsource to third parties. Long-term continuous ECG monitors like Cardea Solo and those provided by other companies, such as iRhythm Technologies Inc. and Preventice Solutions, have been shown to provide clinical benefits over traditional Holter monitors, as extended ECG recorder wear times can increase diagnostic yield by over 25%.

For more information: www.cardiacinsightinc.com

 

Related ECG Content:

6 Trends In ECG Systems

Cardiac Monitoring in the Time of COVID-19: Next Generation Wearable ECG Technology Comes into Its Own

A Double-Edged Sword: How Over-the-Counter ECG Devices are Impacting Cardiac Care

Moving Beyond Holter ECG: The Rise in Next Generation Technology 


Related Content

News | ECG

May 24, 2023 — Rhythm Technologies, Inc., a leading digital health care company focused on creating trusted solutions ...

Home May 24, 2023
Home
News | ECG

May 9, 2023 — Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence (AI)-based medical ...

Home May 09, 2023
Home
News | ECG

April 5, 2023 — Sharing, viewing and storing ECG data into PACS and EMR systems has been a struggle for may institutions ...

Home April 05, 2023
Home
News | ECG

March 27, 2023 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ...

Home March 27, 2023
Home
News | ECG

March 13, 2023 — iRhythm Technologies, Inc., a leading digital health company focused on creating trusted solutions that ...

Home March 13, 2023
Home
News | ECG

December 26, 2022 — AliveCor, the global leader in FDA-cleared personal electrocardiogram (ECG) technology, today ...

Home December 26, 2022
Home
News | ECG

December 1, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences, a medical technology company focused on saving ...

Home December 01, 2022
Home
News | ECG

October 28, 2022 — Heart Test Laboratories, Inc., a medical technology company focused on saving lives by making an ECG ...

Home October 28, 2022
Home
News | ECG

October 19, 2022 — Heart Test Laboratories, Inc. d/b/a HeartSciences, a medical technology company focused on saving ...

Home October 19, 2022
Home
News | ECG

September 29, 2022 — HeartBeam, Inc., a cardiac technology company that has developed the first and only 3D-vector ECG ...

Home September 29, 2022
Home
Subscribe Now